Analyse Cerenome, Inc. (CNSY) — Kairos Score 45/100

À propos de Cerenome, Inc.

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Informations clés

🕴️ Activité des initiés (90 jours)

11 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Cerenome, Inc..

🏦 Hedge Funds

0 fonds institutionnels déclarent une position sur CNSY dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

14 articles récents sur CNSY.

• Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
• Cerenome Launches CNSide® CSF Molecular Profile Tests

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.